183 related articles for article (PubMed ID: 19816720)
1. New molecular scaffolds for the design of Mycobacterium tuberculosis type II dehydroquinase inhibitors identified using ligand and receptor based virtual screening.
Kumar A; Siddiqi MI; Miertus S
J Mol Model; 2010 Apr; 16(4):693-712. PubMed ID: 19816720
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.
Tran AT; West NP; Britton WJ; Payne RJ
ChemMedChem; 2012 Jun; 7(6):1031-43. PubMed ID: 22461418
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Schaeffer's acid analogues as lead structures of mycobacterium tuberculosis type II dehydroquinase using a rational drug design approach.
Schmidt MF; Korb O; Howard NI; Dias MV; Blundell TL; Abell C
ChemMedChem; 2013 Jan; 8(1):54-8. PubMed ID: 23169689
[TBL] [Abstract][Full Text] [Related]
4. Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase.
Petersen GO; Saxena S; Renuka J; Soni V; Yogeeswari P; Santos DS; Bizarro CV; Sriram D
J Mol Graph Model; 2015 Jul; 60():124-31. PubMed ID: 26043661
[TBL] [Abstract][Full Text] [Related]
5. Ligand based virtual screening and biological evaluation of inhibitors of chorismate mutase (Rv1885c) from Mycobacterium tuberculosis H37Rv.
Agrawal H; Kumar A; Bal NC; Siddiqi MI; Arora A
Bioorg Med Chem Lett; 2007 Jun; 17(11):3053-8. PubMed ID: 17418569
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Mycobacterium tuberculosis α-1,4-glucan branching enzyme (GlgB) inhibitors by structure- and ligand-based virtual screening.
Dkhar HK; Gopalsamy A; Loharch S; Kaur A; Bhutani I; Saminathan K; Bhagyaraj E; Chandra V; Swaminathan K; Agrawal P; Parkesh R; Gupta P
J Biol Chem; 2015 Jan; 290(1):76-89. PubMed ID: 25384979
[TBL] [Abstract][Full Text] [Related]
7. Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints.
Kumar A; Siddiqi MI
J Mol Graph Model; 2008 Nov; 27(4):476-88. PubMed ID: 18829358
[TBL] [Abstract][Full Text] [Related]
8. A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors.
Tizón L; Otero JM; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Ainsa JA; Castedo L; González-Bello C
J Med Chem; 2011 Sep; 54(17):6063-84. PubMed ID: 21780742
[TBL] [Abstract][Full Text] [Related]
9. Design and structural analysis of aromatic inhibitors of type II dehydroquinase from Mycobacterium tuberculosis.
Howard NI; Dias MV; Peyrot F; Chen L; Schmidt MF; Blundell TL; Abell C
ChemMedChem; 2015 Jan; 10(1):116-33. PubMed ID: 25234229
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
11. Virtual Screening of potential drug-like inhibitors against Lysine/DAP pathway of Mycobacterium tuberculosis.
Garg A; Tewari R; Raghava GP
BMC Bioinformatics; 2010 Jan; 11 Suppl 1(Suppl 1):S53. PubMed ID: 20122228
[TBL] [Abstract][Full Text] [Related]
12. Prioritization of natural compounds against mycobacterium tuberculosis 3-dehydroquinate dehydratase: A combined in-silico and in-vitro study.
Lone MY; Athar M; Gupta VK; Jha PC
Biochem Biophys Res Commun; 2017 Sep; 491(4):1105-1111. PubMed ID: 28789944
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
[TBL] [Abstract][Full Text] [Related]
14. Nanomolar competitive inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor type II dehydroquinase.
Prazeres VF; Sánchez-Sixto C; Castedo L; Lamb H; Hawkins AR; Riboldi-Tunnicliffe A; Coggins JR; Lapthorn AJ; González-Bello C
ChemMedChem; 2007 Feb; 2(2):194-207. PubMed ID: 17245805
[TBL] [Abstract][Full Text] [Related]
15. Structural insight into Mycobacterium tuberculosis maltosyl transferase inhibitors: pharmacophore-based virtual screening, docking, and molecular dynamics simulations.
Sengupta S; Roy D; Bandyopadhyay S
J Biomol Struct Dyn; 2015; 33(12):2655-66. PubMed ID: 25669125
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling of a series of dehydroquinate dehydratase type II inhibitors of Mycobacterium tuberculosis and design of new binders.
Miranda PHS; Lourenço EMG; Morais AMS; de Oliveira PIC; Silverio PSSN; Jordão AK; Barbosa EG
Mol Divers; 2021 Feb; 25(1):1-12. PubMed ID: 31820222
[TBL] [Abstract][Full Text] [Related]
17. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and drug repurposing strategies.
Hamza A; Wagner JM; Wei NN; Kwiatkowski S; Zhan CG; Watt DS; Korotkov KV
J Chem Inf Model; 2014 Oct; 54(10):2834-45. PubMed ID: 25229183
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
Saxena S; Abdullah M; Sriram D; Guruprasad L
J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
[TBL] [Abstract][Full Text] [Related]
19. Determination of the bound conformation of a competitive nanomolar inhibitor of mycobacterium tuberculosis type II dehydroquinase by NMR spectroscopy.
Prazeres VF; Sánchez-Sixto C; Castedo L; Canales A; Cañada FJ; Jiménez-Barbero J; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2006 Sep; 1(9):990-6. PubMed ID: 16952136
[TBL] [Abstract][Full Text] [Related]
20. Hierarchical virtual screening for the discovery of new molecular scaffolds in antibacterial hit identification.
Ballester PJ; Mangold M; Howard NI; Robinson RL; Abell C; Blumberger J; Mitchell JB
J R Soc Interface; 2012 Dec; 9(77):3196-207. PubMed ID: 22933186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
